Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 819 results for "eli lilly"

Potential Eli Lilly (LLY) Trade Has 1.63% Downside Protection

MarketIntelligenceCenter.comaEUR(TM)s patented algorithms have chosen the Nov. '14 $65.00 call for a couple of hedged-trading ideas on Eli Lilly and Co ("LLY). A traditional covered call on Eli Lilly ..., 1 day ago
Eli Lilly (LLY) Showing Resistance Near $62.99, 1 week ago

69 images for eli lilly

American Banking News, 2 days ago
Mideast Time, 3 days ago
BioSpace, 4 days ago
Jutia Group, 5 days ago
Jutia Group, 5 days ago
Yahoo! Finance, 1 week ago
Vineyard Gazette, 2 days ago
Drug Store News, 4 days ago
Jutia Group, 5 days ago
PR Newswire, 5 days ago

Eli Lilly-Boehringer Drug's Cost Effectiveness Questioned

Eli Lilly and Company ( LLY ) and partner Boehringer Ingelheim are facing an issue related to Jardiance (empagliflozin) in the UK. The National Institute for Health and Care Excellence ( NICE ) has requested for additional information to validate ...
 Yahoo! Finance1 day ago Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod  Yahoo! Finance1 week ago Eli Lilly Gets Tentative FDA Approval For Diabetes Drug  Bidness Etc1 week ago

Eli Lilly, Takeda To Pay $9 Billion In Punitive Damages

Eli Lilly and Takeda were not able to overturn the $9 billion in punitive damages they were ordered to pay for hiding the cancer risks associated with their Type II diabetes drug, Actos. Eli Lilly could sidestep its portion of the punishment, thanks ...
 Bidness Etc1 day ago Takeda, Eli Lilly fail to overturn US jury award of $9 billion in damages over Actos  FirstWord Pharma1 day ago Takeda, Eli Lilly fail in bid to reverse US jury award of $9 billion in damages over Actos  FirstWord Pharma1 day ago

Mylan A Tough Contender In The Biosimilar Anti-Diabetes Race

Mylan is going head-to-head with other pharmaceutical giants like Eli Lilly and Merck in competing to launch a biosimilar of Sanofi\\'s drug Lantus, which is expected to go off-patent by early 2015 Page 1 of 2 Published: August 29, 2014 at ...
 Bidness Etc1 day ago

Shares of Eli Lilly Rank the Highest in Terms of PEG Ratio in the Pharmaceuticals Industry (LLY, PFE, TEVA, MRK, NVS)

(Comtex SmarTrend(R)) Below are the three companies in the Pharmaceuticals industry with the highest price to earnings to growth (PEG) ratios. PEG is valuable in assessing the tradeoff between the price of a stock and expected growth. Generally, ...
 Individual.com1 day ago

Cost watchdogs bar Boehringer, Lilly's diabetes med Jardiance--for now

NICE's Carole Longson Just as Eli Lilly ($LLY) and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of ...
 FiercePharma2 days ago Eli Lilly and Boehringer receive tentative approval for diabetes drug  Individual.com3 days ago Boehringer Ingelheim Pharmaceuticals announces launch of Jardiance prescription tablets for adults with type 2 diabetes (T2D) in the US stores  Individual.com3 days ago Boehringer and Lilly launch type 2 diabetes drug Jardiance in US with prescription  Pharmaceutical Business Review3 days ago

Jardiance type 2 diabetes tablets ship to pharmacies

RIDGEFIELD, Conn., and INDIANAPOLIS Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have released Jardiance tablets (empagliflozin) to U.S. pharmacies. The companies said Tuesday that the type 2 diabetes treatment is now available ...
 Chain Drug Review3 days ago Lilly, Boehringer Say Jardiance Tablets For Type 2 Diabetes Available In U.S.  RTTNews.com4 days ago Lilly Diabetes Treatment Now Available  Inside INdiana Business4 days ago

Ixekizumab superior to etanercept in psoriasis trials

Ixekizumab (Eli Lilly) has demonstrated superiority to etanercept (Enbrel, Amgen) in phase 3 studies for the treatment of moderate-to-severe plaque psoriasis. In three studies, patients were assigned to receive ixekizumab (80 mg every two or four ...
 Dermatology Times4 days ago Market Update: Eli Lilly & Company (NYSE:LLY) Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference  MoneyShow.com5 days ago Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference  Barchart5 days ago Eli Lilly and Company To Participate In Morgan Stanley 2014 Global Healthcare Conference  BioSpace5 days ago

Next Resistance Level for Eli Lilly (LLY) is $63.22

Shares of Eli Lilly (NYSE:LLY) have bullishly opened above the pivot of $62.82 today and have reached the first resistance level of $63.01. Should the shares continue to rise, the resistance pivots of $63.22 and $63.62 will be
 Individual.com3 days ago Watch for Shares of Eli Lilly (LLY) to Approach Resistance at $61.67  Individual.com1 week ago
Reuters India

Takeda, Lilly Lose Bid to Get $9 Billion Actos Award Thrown Out

Takeda Pharmaceutical Co. and Eli Lilly & Co. lost a bid to have a judge throw out a combined $9 billion punitive damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine. To contact the reporter on this ...
 Bloomberg2 days ago Takeda, Eli Lilly on the hook for $9B in damages for hiding cancer risk of diabetes drug  MedCity News1 day ago Judge Upholds $9 Billion Actos Damage Award Against Takeda, Lilly  Claims Journal1 day ago Eli Lilly and Company, Takeda Pharmaceutical Co. Ltd. Lose Bid To Overturn $9 Billion Award For Hiding Actos' Cancer Risk  BioSpace1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eli lilly
Get updated on latest news & your favorite topics right in your inbox!
More     Less